Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spire to develop glaucoma laser and plague test

This article was originally published in Clinica

Executive Summary

In order to fulfil a need for a particular type of glaucoma treatment, Spire has received a $124,500 grant from the US National Eye Institute (of the National Institutes of Health) to develop a new surgical laser. According to Spire, there is currently no ideal laser for performing guarded sclerectomies. This involves piercing a tiny hole in the sclera in order to relieve pressure in the eye. The size of the hole is critical, so the laser needs to be very precise.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel